Evidence map›Paper›PMID 37099810›Full record

ArticleBiochemical and biophysical research communications2023

miR-210 promotes hepatocellular carcinoma progression by modulating macrophage autophagy through PI3K/AKT/mTOR signaling.

Shumin Bi, Yidan Zhang, Jia Zhou, Yuanyuan Yao, Jiadong Wang, Miaomiao Fang, Baozhu Li, Changhao Wu, Chunxia Ren

Open access · hybridAbstract read
In one paragraph

Article in Biochemical and biophysical research communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. mTOR Signaling in Macrophages: All Depends on the Context.International journal of molecular sciences · 2025
    Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Shumin BiSchool of Nursing, Anhui Medical University, Hefei, Anhui, PR China.
Yidan ZhangSchool of Nursing, Anhui Medical University, Hefei, Anhui, PR China.
Jia ZhouSchool of Nursing, Anhui Medical University, Hefei, Anhui, PR China.
Yuanyuan YaoSchool of Nursing, Anhui Medical University, Hefei, Anhui, PR China.
Jiadong WangSchool of Nursing, Anhui Medical University, Hefei, Anhui, PR China.
Miaomiao FangSchool of Nursing, Anhui Medical University, Hefei, Anhui, PR China.
Baozhu LiDepartment of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, Anhui, PR China.
Changhao WuFaculty of Health and Medical Sciences, University of Surrey, Guildford, UK. Electronic address: c.wu@surrey.ac.uk.
Chunxia RenDepartment of General Surgery, First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, PR China. Electronic address: rcxjane@163.com.
Anhui Medical University · CNUniversity of Surrey · GB

Funding

Nox Enzymes in Aging Bladder DysfunctionR01AG049321 · NIA · TEMPLE UNIV OF THE COMMONWEALTH · PI BARBE, MARY F · 2016 to 2020
$1.7M
Biotechnology and Biological Sciences Research Council BB/P004695/1NIA NIH HHS R01 AG049321
6 · The paper itself

Abstract

backgroundTumor-associated macrophages (TAMs) play an important role in tumor development. Increasing research suggests that miR-210 may promote the progression of tumor virulence, but whether its pro-carcinogenic effect in primary hepatocellular carcinoma (HCC) is via an action on M2 macrophages has not been examined.

methodsDifferentiation of THP-1 monocytes into M2-polarized macrophages was induced with phorbol myristate acetate (PMA) and IL-4, IL-13. M2 macrophages were transfected with miR-210 mimics or miR-210 inhibitors. Flow cytometry was used to identify macrophage-related markers and apoptosis levels. The autophagy level of M2 macrophages, expression of PI3K/AKT/mTOR signaling pathway-related mRNAs and protein were detected by qRT-PCR and Western blot. HepG2 and MHCC-97H HCC cell lines were cultured with M2 macrophages conditioned medium to explore the effects of M2 macrophage-derived miR-210 on the proliferation, migration, invasion and apoptosis of HCC cells.

resultsqRT-PCR showed increased expression of miR-210 in M2 macrophages. Autophagy-related gene and protein expression was enhanced in M2 macrophages transfected with miR-210 mimics, while apoptosis-related proteins were decreased. MDC staining and transmission electron microscopy observed the accumulation of MDC-labeled vesicles and autophagosomes in M2 macrophages in the miR-210 mimic group. The expression of PI3K/AKT/mTOR signaling pathway in M2 macrophages was reduced in miR-210 mimic group. HCC cells co-cultured with M2 macrophages transfected with miR-210 mimics exhibited enhanced proliferation and invasive ability as compared to the control group, while apoptosis levels were reduced. Moreover, promoting or inhibiting autophagy could enhance or abolish the above observed biological effects, respectively.

conclusionsmiR-210 can promote autophagy of M2 macrophages via PI3K/AKT/mTOR signaling pathway. M2 macrophage-derived miR-210 promotes the malignant progression of HCC via autophagy, suggesting that macrophage autophagy may serve as a new therapeutic target for HCC, and targeting miR-210 may reset the effect of M2 macrophages on HCC.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsMicroRNAsAutophagyCell Line, TumorHumansMacrophagesPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktSignal TransductionTOR Serine-Threonine KinasesMicroRNAsMIRN210 microRNA, humanMTOR protein, humanPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktTOR Serine-Threonine KinasesAutophagyMacrophagemiR-210Primary hepatocellular carcinoma

Identifiers

PMID37099810
PMCPMC11153875
OpenAlexW4366256879

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.